Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jane Q. Liang"'
Autor:
Joachim von Pawel, Luis Paz-Ares, Ian Taylor, Hui Zhang, Pasi A. Jänne, Jaafar Bennouna, Zelanna Goldberg, Lara Carmen Iglesias Docampo, Jim P. Doherty, Cecile B. Mather, Mikhail Shtivelband, Tony Mok, Jane Q. Liang, Kenneth J. O'Byrne, Suresh S. Ramalingam, Joe O'Connell, Adam Pluzanski, Michael Boyer
Publikováno v:
The Lancet Oncology. 15:1369-1378
Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor. Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for dacomitinib compared with erlotinib. We aimed to compare dacomitinib with erlotinib i
Autor:
Hui Zhang, Eric Sbar, Pasi A. Jänne, Jane Q. Liang, Ian Taylor, Suresh S. Ramalingam, Luis Paz-Ares, Michael Boyer, Tony Mok, Kenneth J. O'Byrne
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 27(7)
Background The irreversible epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown if they are superior to the reversible inhibitors. Dacomitinib is an oral, s
Autor:
Fiona H Blackhall, Joe O'Connell, Stephen P. Letrent, Dae Seog Heo, Isabel Bover, Denis C. Talbot, Maciej Krzakowski, Richard G. Frank, Michael Boyer, Ian Taylor, Carlos H. Barrios, A. Campbell, Ana Ruiz-Garcia, Rafael Rosell, Jane Q. Liang, Suresh S. Ramalingam, Keunchil Park
Publikováno v:
Journal of Clinical Oncology. 30:3337-3344
Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non
Autor:
Margaret A. Marshall, Peter Hersey, David F. McDermott, John M. Kirkwood, Jesus Gomez-Navarro, Caroline Robert, C. A. Bulanhagui, Jane Q Liang, Paul Lorigan, Axel Hauschild
Publikováno v:
Clinical Cancer Research. 16:1042-1048
Purpose: This phase II study assessed the antitumor activity of tremelimumab, a fully human, anti–CTL-associated antigen 4 monoclonal antibody, in patients with melanoma. Experimental Design: Patients with refractory/relapsed melanoma received 15 m
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(9)
Autor:
Robert Millham, Pasi A. Jänne, S. Gail Eckhardt, Jeffrey A. Engelman, Ian Taylor, Steven G. Wong, D. Ross Camidge, Jan H.M. Schellens, Carolyn D. Britten, D. S. Boss, Stephen P. Letrent, Edward B. Garon, Jane Q. Liang, Feng Guo
Purpose: PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. This first-in-human study investigated the safety, tolerability, pharmacokinetics, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4eddd1d0570a68bb7bd3932cc043fb5
https://europepmc.org/articles/PMC3048920/
https://europepmc.org/articles/PMC3048920/
Autor:
Luis Paz-Ares, Jane Q. Liang, Suresh S. Ramalingam, Cecile A. Mather, Ian Taylor, Hui Zhang, Michael Boyer, Jim P. Doherty, Tony Mok, Kenneth J. O'Byrne, Joe O'Connell, Pasi A. Jänne
Publikováno v:
Journal of Clinical Oncology. 32:8018-8018
8018 Background: Dacomitinib, an irreversible pan-HER kinase inhibitor, has demonstrated anti-cancer activity in phase 2 studies for patients with EGFR activating mutation and in those with EGFR an...
Autor:
M. Boyer, Masahiro Tsuboi, M. Laniado, T. Nukiwa, Kazuhiko Nakagawa, Hirohisa Yoshizawa, S. Kobayashi, Filip Janku, M. Takeda, Manfred B. Klevesath, Jun Sakakibara-Konishi, W. Uhl, K. Arakawa, Akihiko Gemma, N. Omachi, T. Tsuji, A. Tamiya, T. Yoshino, Yoshiki Ishii, N. Yamamoto, G. Falchook, T. Kawaguchi, Satoshi Oizumi, Luis Paz-Ares, Gerald S. Falchook, Andreas Johne, Y-L. Wu, J-C. Soria, Isamu Okamoto, P. Rougier, S. Atagi, A. Campbell, H. Lannert, Razelle Kurzrock, T. Shiroyama, Siquing Fu, K. Asami, H. Isobe, A. Ohtsu, V. Antic, S.-Y. Lee, K. Park, H. Crane, C.-M. Tsai, Sojiro Morita, Ralph Zinner, Jennifer J. Wheler, M. Wirth, Stephen P. Letrent, Sarina Anne Piha-Paul, Pasi A. Jänne, N. Yoshizuka, M. Tamiya, Tony Mok, K. Takeda, Motoki Yoshida, M. D. Rutstein, J.J. Wheler, H. Suzuki, Thierry Gil, H. Tada, S. Ballal, A. Grothey, S. Zastrow, N. Okamoto, Akira Inoue, Y. Ichinose, K. Sugio, S. Minomo, Aung Naing, Ian Taylor, S. Nakamura, Yoichi Nakanishi, Joe O'Connell, Y. Saijyo, J. T.abernero, Jane Q. Liang, F. Nasroulah, Suresh S. Ramalingam, K. O'Byrne, T. Mitsudomi, Axel Heidenreich, N. Morishita, V. Jego, K. Okishio, K. Yamazaki, Jürgen E. Gschwend, T. Hirashima, David S. Hong, M. Zühlsdorf, T. Yamanaka, D.S. Hong, X. Zhang, Apostolia-Maria Tsimberidou, J. Gerloff, A. Miao, Koichi Hagiwara, Kazuhiko Kobayashi, Hesham M. Amin
Publikováno v:
Annals of Oncology. 23:xi21
Background The cell surface receptor tyrosine kinase c-Met and its ligand, the hepatocyte growth factor (HGF), are implicated in tumor cell migration, invasion, survival and proliferation. EMD 1214063 is a novel potent and highly selective reversible
Autor:
Jane Q. Liang, S.S. Ramalingam, Maciej Krzakowski, L. J. Denis, Fiona H Blackhall, Michael Boyer, Ian Taylor, Joe O'Connell, K. Park, Carlos H. Barrios
Publikováno v:
Journal of Clinical Oncology. 28:LBA7523-LBA7523
LBA7523 Background: PF299804, a potent, irreversible inhibitor of human epidermal growth factor receptor (HER)-1/EGFR, -2, and -4 tyrosine kinases (TK), is active in E-sensitive and -resistant preclinical models. PF299804 had clinical activity in pha
Autor:
Michael Boyer, Ian Taylor, Pasi A. Jänne, Luis Paz-Ares, S.-Y. Lee, Stephen P. Letrent, V. Antic, Joe O'Connell, Tony Mok, A. Campbell, Kenneth J. O'Byrne, Jane Q. Liang, Suresh S. Ramalingam
Publikováno v:
Web of Science
ResearcherID
ResearcherID
Background D is a highly selective irreversible small molecule inhibitor of all catalytically active members of the HER (human epidermal growth factor receptor) family of tyrosine kinases. In a randomized phase II trial in patients (patients) who had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44f0576a986b208eef50072311d16dc6
https://publons.com/wos-op/publon/9297482/
https://publons.com/wos-op/publon/9297482/